Scoop: Rakuten Medical targets year-end close for $100M+ Series E to fund photoimmunotherapy pipeline: #Jefferies23
16 Nov 2023
Immunotherapy
Rakuten Medical is aiming to close its Series E raise before the end of the year, with the funds designed to add fuel to its photoimmunotherapy clinical trials. As of this week, the company has docketed $107-108 million, Endpoints News has learned.
“The market situation is really tough but we are in good shape,” co-CEO and president Takashi Toraishi told Endpoints on the sidelines of the Jefferies healthcare meeting Wednesday. Since the fundraise is still ongoing, Toraishi declined to disclose the exact target size of the raise.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.